Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
|Posted on January 24, 2021 at 6:55 AM|
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.
The double-masked, single-center, parallel-group run-in cohort enrolled 23 patients: 12 patients were randomized to receive 0.25% reproxalap ophthalmic solution and 11 patients were randomized to receive veh...Read Full Post »
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
|Posted on January 10, 2021 at 7:55 AM|
- Ocular Pain, a $10+ billion global market, with significant unmet medical need
- License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies
Irvine, Calif., Paris, Hong Kong, Jan. 7, 2021 /PRNewswire/ — IACTA Pharmaceuticals, Inc. (“IACTA" and Pharmaleads, with Pharmaleads Greater China, today announced they have entered into licensing agreements, with ...Read Full Post »
|Posted on November 28, 2020 at 7:00 AM|
SilkTech Biopharmaceuticals has completed enrollment in a phase 2b clinical trial of SDP-4, its eye drop formulation for the treatment of the signs and symptoms of dry eye disease, according to a press release.
The randomized, double-masked, vehicle-controlled, multicenter trial is evaluating the safety and efficacy of SDP-4 at 0.1%, 1% and 3% concentrations in 305 patients at 25 U.S. sites.
SDP-4, a biotherapeutic naturally derive...Read Full Post »
|Posted on November 16, 2020 at 8:20 AM|
A phase 2b clinical trial of AR-15512 ophthalmic solution for the treatment of dry eye disease has been initiated, according to a press release from Aerie Pharmaceuticals.
COMET-1 is a randomized, double-masked, vehicle-controlled trial investigating the safety and efficacy of AR-15512, a TRPM8 agonist. The trial aims to enroll about 360 patients who will receive AR-15512 0.0014%, AR-15512 0.003% or AR-15512 vehicle, one drop twice daily in e...Read Full Post »
Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease
|Posted on November 7, 2020 at 5:55 PM|
Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced a US$20 million financing. The round was led by a syndicate of existing investors including OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund (MRCF) and Ganot Capital.
On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance AzuraR...Read Full Post »